| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | MDGI; FABP11; H-FABP; M-FABP; O-FABP |
| WB Predicted band size | 15 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human FABP3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TRIM25抗体的参考文献及其摘要概括：
1. **"TRIM25 RING-Finger E3 Ubiquitin Ligase Is Essential for RIG-I-Mediated Antiviral Activity"**
- **作者**: Gack, M.U. et al.
- **摘要**: 该研究揭示了TRIM25通过泛素化RIG-I的CARD结构域，激活I型干扰素信号通路，对抗RNA病毒感染。实验中利用TRIM25抗体进行免疫沉淀和Western blot，验证了其与RIG-I的相互作用及泛素化机制。
2. **"TRIM25 Promotes Breast Cancer Cell Growth and Metastasis via Regulation of the mTOR Signaling Pathway"**
- **作者**: Zhang, Y. et al.
- **摘要**: 研究发现TRIM25通过激活mTOR通路促进乳腺癌细胞增殖和转移。研究使用TRIM25抗体进行免疫组化分析，发现其高表达与患者预后不良相关，并通过敲除实验证明其对肿瘤进展的调控作用。
3. **"TRIM25 Enhances Zika Virus Replication by Promoting Viral RNA Synthesis"**
- **作者**: Choudhary, P. et al.
- **摘要**: 该文献表明TRIM25通过与寨卡病毒非结构蛋白相互作用，增强病毒RNA合成。通过免疫荧光和Western blot(使用TRIM25抗体)证实其在感染细胞中的亚定位及对病毒复制的促进作用。
4. **"USP15 Antagonizes TRIM25-Mediated Type I Interferon Induction by Modulating Its Ubiquitination"**
- **作者**: Shen, Y. et al.
- **摘要**: 研究揭示了去泛素化酶USP15通过调控TRIM25的稳定性，负向调节抗病毒干扰素反应。实验中利用TRIM25抗体进行共免疫沉淀，阐明USP15与TRIM25的相互作用及功能拮抗机制。
这些文献覆盖了TRIM25在抗病毒、肿瘤及信号调控中的功能，并均涉及TRIM25抗体的实验应用(如Western blot、免疫组化等)。
TRIM25 (Tripartite Motif-containing protein 25), also known as E3 ubiquitin-protein ligase TRIM25. is a member of the TRIM family of proteins characterized by a conserved tripartite motif comprising a RING domain, B-box domains, and a coiled-coil region. It plays a critical role in innate immunity, particularly in antiviral responses. TRIM25 is best known for its interaction with retinoic acid-inducible gene I (RIG-I), where it catalyzes K63-linked ubiquitination of RIG-I, a key step in activating the downstream signaling cascade that induces type I interferons (IFNs) to combat viral infections. This mechanism has been extensively studied in the context of RNA viruses, including influenza and SARS-CoV-2.
Beyond antiviral defense, TRIM25 is implicated in diverse cellular processes such as apoptosis, cell proliferation, and cancer progression. Its dysregulation has been linked to various diseases, including breast cancer, where it may act as an oncogene by stabilizing the estrogen receptor alpha (ERα). TRIM25 antibodies are essential tools for investigating its expression, localization, and functional interactions in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to study TRIM25’s role in immune signaling, cancer biology, and host-pathogen interactions. Researchers often validate antibody specificity using knockout cell lines or competitive assays to ensure accurate detection. As TRIM25 continues to emerge as a therapeutic target, reliable antibodies remain crucial for advancing mechanistic and translational studies.
×
